Dear GTMC Secretariat
RE: REVIEW OF THE GENE TECHNOLOGY ACT 2000
Monsanto Australia welcomes the opportunity to contribute to the Review of the Gene Technology Act 2000 that was announced on Thursday 26 May.
Monsanto is an agricultural company that applies innovation and technology to help farmers around the world produce more while conserving more. We help farmers grow yield sustainably so they can be successful, produce healthier foods, better animal feeds and more fiber, while also reducing agriculture's impact on our environment. In the period that the Gene Technology Act 2000 has been in force, we have been one of the very few companies to bring gene technology products in market in Australia, and have conducted numerous regulated field trials under the legislation. We therefore feel that we are in a strong position to provide comment for this review.
In the first instance, we would like to stress our support for the current Gene Technology Act, as administered by the Office of the Gene Technology Regulator (OGTR). The Act provides certainty for innovators by establishing a process that is both transparent and has clear timeframes, while at the same time introducing a comprehensive risk assessment framework. In addition, it is clearly accessible to interested members of the public and accountable to Federal Parliament. The staff at the OGTR does an excellent job in administering this legislation and in carrying out the Objective of the Act. As a result, Monsanto does not believe that there is a need to make large scale changes to the processes established by this regulatory scheme. Rather, this Review should be used to reinforce all jurisdictions' commitment to a national regulatory scheme for gene technology, and to address aspects that were not foreseen at the time of drafting of this legislation.
In this regard, Monsanto supports the submission from CropLife Australia. We believe that data protection, regulatory duplication and over-regulation, and product discontinuation are important issues that have not been adequately addressed under the Gene Technology Act to date, and which require further consideration.
The introduction of a data protection scheme, as is the case for similar innovations in Australia (such as agricultural chemicals) would be welcome, and has been a request of industry for many years. We would propose a fifteen year protection time-span, especially with patents about to expire.
Discontinued products are authorized commercial plant biotechnology seed products that have reached the end of their commercial life cycle. While sales have terminated, grain and plant-derived products may still be present in the food, feed and grain supple (please note that this is a distinctly different situation from a product recall). Product discontinuance is the process by which sales of an authorized commercial seed product are terminated, including a) cessation of commercial sales; b) use of quality management practices to minimize the presence of the discontinued product in other seed; c) notification of key stakeholders that the product has been discontinued; d) coverage of regulatory needs and e) where applicable, varietal deregistration or de-listing. Discontinues products need to be addressed with case-by-case solutions, in discussions with the registrant,since low level presence may dissipate at different rates for difference products based on commodity use patterns outside the registrant's control. There products should also be exempt from now or ongoing regulatory requirements (such as annual reporting or costly monitoring where no incremental value is provided).
Monsanto also sees this Review as an opportunity to address duplication and overlap between the Gene Technology Act and other existing legislation. This leads to increased costs, as well as to uncertainty, difficulty and delay in planning for the commercial introduction of new technology. One only needs to looks at the number of commercially-approved GM crops to see that this is having an effect. We therefore support CropLife Australia's call for the Ministerial Council to direct the Intergovernmental Regulators Forum to review this duplication and any other areas of regulatory overlap.
For biotechnology derived crops, Monsanto also believes that the data requirements on novel breeding techniques should be as low as is reasonable to assure for the protection of food, feed and environmental safety based on the nature and characteristics of the product. Safety assessments should be driven by characteristics of the product, rather than evaluating risk based on the process used to produce the product. Given the characteristics of biotechnology derived products and the demonstrated history of safe utilisation of these products, regulations and data requirements on transgenic biotechnology products should be evaluated and excessive requirements lowered.
Not only is there duplication and uncertainty during the application process,but the history of the introduction of GM canola into Australia clearly demonstrates that difficulties also currently exist once commercial approval is actually received from all regulators (OGTR, APVMA and FSANZ). The introduction of State legislation and moratoria has significantly impacted the ability of innovators in Australia to bring gene technology products to market. Monsanto itself has been directly impacted by these decisions, having received commercial approval for Roundup Ready canola in 2003, and still not having the ability to offer this new technology to all growers in Australia who want it, or even for this approved gene technology trait to be able to be transported through some States. Not only that, but there continues to be attempts by local councils and others to prevent the trails of out second generation GM canola, which will increase the glyphosate application window for farmers (as Roundup Ready Flex has done). We continue to invest in Australia, but fewer and fewer companies are doing so. The 2006 Review of the Gene Technology Act recommended that the Commonwealth and States, through the Gene Technology Ministerial Council, reconfirm their commitment to a nationally consistent scheme for gene technology, and it is now time for this recommendation to be fully and completely implemented.
Monsanto would also like to use the opportunity of this Review to highlight the increased use of administrative conditions on field trial licences. Licences nowadays, for example, require a significant number of notifications (eg: planned planting date, actual planting date, estimated flowering date, actual flowering date, expected harvest date, actual harvest date) during the trial period which we believe are not related to risk, but more to ease of auditing. Some of these also have different notification deadlines to others. This may actually prove to be counteractive to ensuring compliance, and adds to the costs of conducting field trials. Licence conditions (including those associated with authorised persons, transport, monitoring and reporting) should reflect the realities that they are being introduced to address, rather than being too specific - otherwise they run the risk of being too prescriptive and unmanageable from a regulatory perspective (please see CropLifes Australia's submission to the review of the Gene Technology Regulations as an example).
Thank you again for the opportunity to make a submission to this Review. We would also welcome an opportunity to discuss any of these aspects in more detail with the Ministerial Council, given Monsanto's extensive and successful experience with the Gene Technology Act, as well as with other such regulatory frameworks around the world.
Yours sincerely
Michael Leader
Regulatory Affairs Lead
Original submission in PDF format (PDF 330 KB)
In this section
- Occasional papers series
- Plasma Fractionation Review
- Regulatory Plan 2007-08
- Regulatory Plan 2008-09
- Regulatory Plan 2006-07
- Department of Health Reconciliation Action Plan
- PHERP Review Reports
- Margaret River Consumer for GM Free Food Submission to the review Gene Technology Act 2000
- 2002 Reviews of the National HIV/AIDS and Hepatitis C Strategies and Strategic Research
- 2006 Aged Care Homes Survey
- 2006 – 2007 Jurisdictional Summary Report against the National Strategic Framework for Aboriginal and Torres Strait Islander Health (NSFATSIH)
- A National Aboriginal Health Strategy: An Evaluation 1994
- Alcohol and other drugs: a handbook for health professionals
- Alerting the community to the link between illicit drugs and mental illness: developmental research
- An analysis of research on preventing falls and falls injury in older people: Community, residential care and hospital settings (2004 update)
- Anorexia nervosa: Australian treatment guide for consumers and carers, 2005
- Building on success 1: a review of gay and other homosexually active men's HIV/AIDS education in Australia
- Building on success 2: towards a national strategy for HIV/AIDS health promotion for gay and other homosexually active men
- Building on success 3: the Commonwealth Government response to towards national strategy for HIV/AIDS health promotion for gay and other homosexually active men
- COAG mental health early intervention measure - early childhood component: study to scope potential service delivery
- Coping with depression: Australian treatment guide for consumers and carers, 2005
- Council Of Grain Grower Organisations submission to the Gene Technology Act 2000 Review
- Deakin University submission to the Gene Technology Act 2000 review
- Deep vein thrombosis and air travel
- Department of Health and Ageing (DoHA) - Medicare Australia Memorandum of Understanding (MoU)
- Discussion Document Towards a Fourth National HIV/AIDS Strategy April 1999
- Drug and Alcohol Service Report (DASR): 2006-2007 Key Results
- Drug and Alcohol Service Report (DASR): 2007-2008 Key Results
- Evidence of effective interventions to improve the social and environmental factors impacting on health: Informing the development of Indigenous Community Agreements
- Falls prevention activities for older people: a national stocktake
- Gene technology Act 2000 review from Guy Izzett
- gettin em n keepin em
- Government response to the House of Representatives Inquiry into Indigenous health: 'Health is life'
- Innovative grants program: project summaries
- MAIF Guidelines - Marketing Of Infant Formulas Via Electronic Media
- Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA) Revised Edition. Occasional Papers: New Series Number 14
- National evaluation of the Sharing Health Care Initiative demonstration projects
- National HIV/AIDS Strategy 2005-2008: Implementation Plan
- National Strategic Framework for Aboriginal and Torres Strait Islander Health Context July 2003
- National strategy for heart, stroke and vascular health in Australia
- Panic disorder and agoraphobia: Australian treatment guide for consumers and carers, 2005
- Principles for the consideration of interactions with health care professionals for the purpose of interpreting the MAIF Agreement
- Public discussion paper - Adoption of the Globally Harmonised System for Classification and Labelling of Chemicals in Respect to Domestic and Consumer Chemicals Including Pesticides
- Quality Use of Pathology Program (QUPP) Historical Reports
- Reforming the Australian
health care system:
the role of government. Occasional Papers: New Series Number 1
- Regulatory Plan 2009-10
- Regulatory Plan 2010-11
- Regulatory Plan 2011-2012
- Review of 2011 Gene Technology ACT (2000) - Public Submission
- Review of the Gene Technology Act 2000
- Review of the Gene Technology Act 2000 by Anne Goddard
- Review of the Gene Technology Act 2000 from I F Turnbull
- Review of the Gene Technology Act 2000 from Slater & Gordon Lawyers on behalf of The Safe Food Institute
- Royal Perth Hospital Comments on the Gene Technology Review 2000
- Self-harm: Australian treatment guide for consumers and carers, 2005
- Stigma and discrimination
- Strong Fathers Strong Families
- Submission by Anne Goddard regarding Terms of Reference in the Gene Technology Act 2000
- Submission by Dr Monica Leggett to the Gene Technology Act 2000 review
- Submission by the Office of the Gene Technology Regulator to the Review of the Gene Technology Act 2000
- Submission by The University of Newcastle for the 2011 Review of the Gene Technology Act 2000
- Submission from Bayer CropScience to the Gene Technology Act 2000 Review
- Submission from AgForce to the Statutory Review of the Gene Technology Act 2000
- Submission from Agrifood Awareness Australia Limited reviewing the Gene Technology Act 2000
- Submission from an Individual to the Review of Gene Technology Act 2000
- Submission from an Individual to the Review of the Gene Technology Act 2000
- Submission from AusBiotech to the 2011 Review of the Gene Technology Act 2000 (the Act)
- Submission from Beatrice Ludwig to the 2011 Review of the Gene Technology Act
- Submission from Croplife Australia to the Review of the Gene Technology Act 2000
- Submission from Department of Agriculture, Fisheries and Foresty to the Review of the Gene Technology Act 2000
- Submission from Elizabeth Hamilton to the 2011 Review of the Gene Technology Act 2000
- Submission from Graham Wearne to the Gene Technology Act 2000 Review
- Submission from Individuals at the Institutional Biosafety Committee to the Gene Technology Act 2000 Review
- Submission from Individuals to the Review of Gene Technology Act 2000
- Submission from Monsanto to the Review of the Gene Technology Act 2000
- Submission from Nuseed Australia to the Review of the Gene Technology Act 2000
- Submission from Peter Olson to the Review of Gene Technology Act 2000
- Submission from Queensland Institute of Medical Research to the Review of Gene Technology Act 2000
- Submission from the Australian Seed Federation to the Statutory Review of the Gene Technology Act 2000
- Submission from the Department of Innovation, Industry, Science and Research and The Commonealth Scientific and Industrial Research Organisation to the 2011 Review of the Gene Technology Act (2000)
- Submission from the Gene Technology Interdepartmental Committee to the Review of the Gene Technology Act 2000
- Submission from the GM-free Australia Alliance to the Review of the Gene Technology Act 2000
- Submission from the Grains Research and Development Corporation to the 2011 Review of the Gene Technology Act 2000
- Submission from the National Association for Sustainable Agriculture Australia WA Inc to the Review of the Gene Technology Act 2000
- Submission from the National Farmers' Federation review to the Gene Technology Act 2000
- Submission from the Producers Forum to the Review of the Gene Technology Act 2000
- Submission from the Western Australian Farmers Federation Review of the Gene Technology Act 2000
- Submission to the Gene Technology Act 2000 Review by Mary Gardner
- Submission to the Gene Technology Act 2000 Review from the Minister for Primary Industries and Water
- Submission to the Review of Gene Technology Act 2000 from Phil Aitken
- Submission to the Review of Gene Technology Act 2000 from Organic and Biodynamic Meats
- Submission to the Review of Gene Technology Act 2000 from Tracey Skippings
- Sumbission from Individuals from the Wambyn Organic Olive Farm for the Gene Technology Act 2000
- Sumission to the Department of Health and Ageing from the Pioneer Hi-Bred Australia Pty Ltd to the Review of the Gene Technology Act 2000 (the Act)
- Technology, Health and Health Care. Occasional Papers: Health Financing Series Volume 5
- The Ageing Australian Population and Future Health Costs: 1996-2051. Occasional Papers: New Series Number 7
- The Australian Government Response to the 2002 Reviews of the National HIV/AIDS and Hepatitis C Strategies
- The Dairy Industry Submission to the Statutory Review of the Gene Technology Acy 2000
- The National Hepatitis C Strategy 2005-2008
- The National Slips and Falls Prevention Project
- The Quality of Australian Healthcare: Current Issues and Future Directions. Occasional Papers: Health Financing Series Volume 6
- The Use of Antibiotics in Food-Producing Animals: Antibiotic-Resistant Bacteria in Animals and Humans
- Training frontline workers: young people, alcohol and other drugs
- Using Mathematical Models to Assess Responses to an Outbreak of an Emerged Viral Respiratory Disease
- Valuing the past ... investing in the future- Evaluation of the National HIV /AIDS Strategy 1993-94 to 1995-96
- Trachoma Surveillance Report 2006 to 2010
- Regulatory Plan 2005-06
- Regulatory Plan 2004-05
- Regulatory Plan 2003-04